Special Issue

Botulinum Toxins: New Uses in the Treatment of Diseases

Message from the Guest Editor

Both animal and clinical studies have extensively reported the therapeutic efficacy of botulinum neurotoxins (BoNTs) in many diseases characterized by excessive muscle contractions. Since the therapeutic effects of BoNTs reside in their elective action as inhibitors of cholinergic transmission, this has given extraordinary support to the clinical use of BoNTs in pathologies such as dystonia, torticollis, blepharospasm, and many others originating from hypercholinergic dysfunctions. This Special Issue, entitled "Botulinum Neurotoxins: Employ in the Treatment of Diseases", is particularly dedicated to the collection of research on new therapeutic applications of BoNTs, both as native and engineered toxins. Both review and research articles on animal models, clinical studies, case reports, or off-label indications are welcome. The ambitious goal of this Special Issue is to provide an updated framework on the development of new applications of BoNTs for their future clinical use.

Guest Editor

Dr. Siro Luvisetto

Institute of Biochemistry and Cell Biology, National Council of Research of Italy, Via Ercole Ramarini 32, 00015 Monterotondo, Italy

Deadline for manuscript submissions

closed (10 April 2023)

MDPI

Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed

mdpi.com/journal/
toxins

About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox
Department of Microbiology, University of Virginia, Charlottesville, VA, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:
JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.4 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).